Key facts today
Novo Nordisk cut its 2025 sales growth outlook to 8-14% and operating profit forecast to 10-16%, citing slower growth for Ozempic and Wegovy, causing a 25% pre-market drop.
Novo Nordisk's Alhemo has gained FDA approval as a daily treatment to prevent bleeding episodes in adults and children 12 and older with Hemophilia A or B without inhibitors.
On June 23, 2025, Novo Nordisk ended its partnership with Hims & Hers Health over concerns of misleading marketing related to Wegovy®, citing unauthorized promotion and sales violations.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.4 USD
14.65 B USD
42.12 B USD
3.37 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
FIGI
BBG00JVRG3N5
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
$NVO Accumulating long term compounder! - Previously, I have shorted NYSE:NVO when it was in $75-85 when moat was weakening and then went long around $58 to $75 for 40% on the long side. Everything is documented in my two posts.
- People are asking me if NYSE:NVO is cheap or not. After cutting guidance, I believe most of the estimat
Fib resistance + RSI bullish reversal After the bearish news earlier today, it seems like Novo has had its final capitulation.
There's a fib resistance + historical resistance dating back to '21-'22.
On the weekly, the RSI is also presenting a bullish divergence - although we may want to await the closing of this week to confirm this.
T
NVO going to zero? Just zoom out V.2While many are panic, just zoom out years and we can dee that it is at 30 years support trend line to the upside.
Weekly RSI printing bullishvergent, monthly at Oversold level.
Still fundamentally strong, If you love this stock, be excited.
(Last post chart didn't appear properly, I couldn't edit
Is Novo Nordisk a buy? Novo Nordisk $NYSE: NVO plummets 22% on July 29, wiping out $57.5B in market value!
Here's what's happening and how I see it.
Here’s the breakdown on why the stock hit its lowest since Nov 2022:
Slashed 2025 Guidance: Sales growth cut to 8–14% from 13–21%, operating profit to 10–16% from 16–2
NVO Could Bounce Back Soon ?!NVO dropped hard (over 20%) mainly because of a legal issue. I think this is temporary and will get solved with time. The stock is now super oversold and sitting on strong support around $52–53.
• Entry: $52–54
• Target 1: $56.90
• Target 2: $66.40
• Stop Loss: $50
If the issue clears, we could
Novo Nordisk, generational buying opportunity? Novo Nordisk is currently experiencing one of the largest drawdowns in its history, primarily triggered by a downward revision of guidance for FY25 and FY26.
Focusing strictly on technical analysis:
For the first time, the monthly 200 EMA is serving as a key support level for Novo Nordisk -
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where 0TDD is featured.